Actuate Therapeutics Unveils Compelling Trial Outcomes for Advanced Salivary Gland Malignancies

Actuate Therapeutics, Inc. (ACTU) announced on Monday encouraging findings from its Phase II clinical investigation of elraglusib combined with standard chemotherapy agents carboplatin or cisplatin in patients suffering from advanced metastatic salivary gland cancers. The trial population comprised 47% adenoid cystic carcinoma (ACC) patients and 53% with other histological subtypes affecting the gland tissue.

The efficacy data demonstrated substantial clinical promise. Participants achieved a median overall survival of 18.6 months, with survival rates reaching 58% at the one-year mark and maintaining at 40% through the two-year follow-up period. Among the non-ACC patient cohort, median overall survival extended to 27.8 months, representing a notable improvement for this historically challenging patient population.

Progression-free survival metrics further highlighted the treatment’s potential. The median PFS reached 6.4 months across the study population, with 27% of enrolled patients sustaining progression-free status at one year. These figures represent a significant advancement when compared to historical control data, which showed approximately 49 months median PFS for ACC patients treated with conventional approaches and less than 6 months for non-ACC patients—marking a meaningful shift in treatment landscape for these malignancies of the salivary gland.

The comprehensive trial results have now been published in the peer-reviewed journal Clinical Cancer Research, establishing a formal record of these findings in the scientific literature. Market sentiment regarding these results proved positive, with Actuate’s stock appreciating over 4% in pre-market trading sessions. The company’s shares closed Friday at $7.52, reflecting a 1.35% gain from the previous trading session.

Disclaimer: The views and opinions expressed herein are the author’s perspectives and do not necessarily represent those of Nasdaq, Inc.